🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-527107-22-00
Authorised Phase IV

ACTOR – AUC Control of Tacrolimus in Organ Recipients

2026-527107-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
Oslo Universitetssykehus HF
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Therapeutics
Decision date
02/09/2026
Enrollment target
24
Sites
Norway

Condition studied

Kidney transplantation

Investigational medicinal product(s)

PROGRAF 1 mg capsule

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

AUC0-12 (rich sampled)

Endpoint detail

AUC0-12 (limited sampling, 3 points), intra-individual coefficient of variation (CV%) of the AUC0-12/C0 ratio, microbiome metagenomics

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527107-22-00 on CTIS ↗ ← All trials in the EU